Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

By E. Bouffet, Valérie Larouche, B. Campbell, Daniele Merico, Richard de Borja, M. Aronson, C. Durno, J. Krueger, V. Cabric, V. Ramaswamy and 32 more. Journal of Clinical Oncology, 2016

735 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/4d26bc4739c82041902ea2e51e7f7a89a36274a9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Joyce
2. R. DePinho
3. Simone Fulda

In Genetics

1. Suzanne J. Baker
2. J. Joyce
3. D. Quail
4. R. DePinho

In Pathology and Forensic Medicine

1. J. Joyce
2. Simone Fulda

Citations in the corpus

• The landscape of genomic alterations across childhood cancers (2018, positive): “This may also transcend the direct targeting of genes or pathways, for example, through immune checkpoint inhibition in hypermu-tated tumours 13 or through PARP inhibition in genomically unstable (‘BRCAness’) tumours 48 .”
• Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma (2017, background): “The remarkable biological diversity spanning pediatric malignant glioma is finally demonstrated by the 5% tumors with a hypermutator phenotype, some of the greatest mutational burdens in all human cancer, and candidates for immune checkpoint inhibitors (Bouffet et al., 2016).”
• FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors (2019, background): “A concern raised during the reviewof the application resulted in a requirement to conduct assessment of safety and activity in pediatric patients with central nervous system (CNS) malignancies, givenpublished literature reports of antitumor responses and cerebral edema following checkpoint inhibitio”
• The microenvironmental landscape of brain tumors (2017, background): “A recent clinical study in pediatric gliomas showed that nivolumab treatment of recurrent hypermutant glioblastoma in two siblings with biallelic mismatch repair deficiency led to a significant and sustained therapeutic response (Bouffet et al., 2016).”
• Comprehensive Analysis of Hypermutation in Human Cancer (2017, positive): “We also note that this coincides with the median mutation burden of patients previously reported to respond to checkpoint inhibition (Bouffet et al., 2016; Diaz and Le, 2015; Johanns et al., 2016; Le et al., 2015; Rizvi et al., 2015; Santin et al., 2016; Snyder et al., 2014; Van Allen et al., 2015).”
• Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2017, background): “This subset of patientsmay be responsive to checkpoint inhibition blockade, to which limited successes have been reported (Bouffet et al., 2016; Johanns et al., 2016).”